William Plovanic, an analyst from Canaccord Genuity, reiterated the Buy rating on TriSalus Life Sciences. The associated price target remains the same with $11.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
William Plovanic has given his Buy rating due to a combination of factors including the company’s strategic positioning and product pipeline. Despite lowering revenue estimates, Plovanic maintains confidence in TriSalus Life Sciences’ long-term potential, particularly in the liver market. The introduction of new products such as TriNav Large, TriGuide, and TriNav Flex is expected to enhance market adoption and drive future growth.
Furthermore, Plovanic anticipates that the company will achieve adjusted EBITDA positivity by the second quarter of 2026. Although there is an expectation of a slower ramp in profitability due to reinvestments in the commercial organization, the overall outlook remains positive. The reaffirmation of the $11 price target reflects Plovanic’s belief in the company’s ability to capitalize on its opportunities and sustain growth.